Cargando…
Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature
Multiple sclerosis (MS) is a chronic, inflammatory and immune-mediated disease of the central nervous system (CNS), commonly affecting young adults and potentially associated with life-long disability. About 14 disease-modifying treatments (DMTs) are currently approved for the treatment of MS. Howev...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875789/ https://www.ncbi.nlm.nih.gov/pubmed/35207216 http://dx.doi.org/10.3390/jcm11040942 |
_version_ | 1784658016571752448 |
---|---|
author | Patti, Francesco Chisari, Clara Grazia Toscano, Simona Arena, Sebastiano Finocchiaro, Chiara Cimino, Vincenzo Milone, Giuseppe |
author_facet | Patti, Francesco Chisari, Clara Grazia Toscano, Simona Arena, Sebastiano Finocchiaro, Chiara Cimino, Vincenzo Milone, Giuseppe |
author_sort | Patti, Francesco |
collection | PubMed |
description | Multiple sclerosis (MS) is a chronic, inflammatory and immune-mediated disease of the central nervous system (CNS), commonly affecting young adults and potentially associated with life-long disability. About 14 disease-modifying treatments (DMTs) are currently approved for the treatment of MS. However, despite the use of highly effective therapies, some patients exhibit a highly active disease with an aggressive course from onset and a higher risk of long-term disability accrual. In the last few years, several retrospective studies, clinical trials, meta-analyses and systematic reviews have investigated autologous hematopoietic stem cell transplantation (AHSCT) as a possible therapeutic option in order to address this unmet clinical need. These studies demonstrated that AHSCT is a highly efficacious and relatively safe therapeutic option for the treatment of highly active MS. Particularly, over recent years, the amount of evidence has grown, with significant improvements in the development of patient selection criteria, choice of the most suitable transplant technique and clinical experience. In this paper, we present six patients who received AHSCT in our MS center and we systematically reviewed recent evidence about the long-term efficacy and safety of AHSCT and the placement of AHSCT in the rapidly evolving therapeutic armamentarium for MS. |
format | Online Article Text |
id | pubmed-8875789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88757892022-02-26 Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature Patti, Francesco Chisari, Clara Grazia Toscano, Simona Arena, Sebastiano Finocchiaro, Chiara Cimino, Vincenzo Milone, Giuseppe J Clin Med Review Multiple sclerosis (MS) is a chronic, inflammatory and immune-mediated disease of the central nervous system (CNS), commonly affecting young adults and potentially associated with life-long disability. About 14 disease-modifying treatments (DMTs) are currently approved for the treatment of MS. However, despite the use of highly effective therapies, some patients exhibit a highly active disease with an aggressive course from onset and a higher risk of long-term disability accrual. In the last few years, several retrospective studies, clinical trials, meta-analyses and systematic reviews have investigated autologous hematopoietic stem cell transplantation (AHSCT) as a possible therapeutic option in order to address this unmet clinical need. These studies demonstrated that AHSCT is a highly efficacious and relatively safe therapeutic option for the treatment of highly active MS. Particularly, over recent years, the amount of evidence has grown, with significant improvements in the development of patient selection criteria, choice of the most suitable transplant technique and clinical experience. In this paper, we present six patients who received AHSCT in our MS center and we systematically reviewed recent evidence about the long-term efficacy and safety of AHSCT and the placement of AHSCT in the rapidly evolving therapeutic armamentarium for MS. MDPI 2022-02-11 /pmc/articles/PMC8875789/ /pubmed/35207216 http://dx.doi.org/10.3390/jcm11040942 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Patti, Francesco Chisari, Clara Grazia Toscano, Simona Arena, Sebastiano Finocchiaro, Chiara Cimino, Vincenzo Milone, Giuseppe Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature |
title | Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature |
title_full | Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature |
title_fullStr | Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature |
title_full_unstemmed | Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature |
title_short | Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature |
title_sort | autologous hematopoietic stem cell transplantation in multiple sclerosis patients: monocentric case series and systematic review of the literature |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875789/ https://www.ncbi.nlm.nih.gov/pubmed/35207216 http://dx.doi.org/10.3390/jcm11040942 |
work_keys_str_mv | AT pattifrancesco autologoushematopoieticstemcelltransplantationinmultiplesclerosispatientsmonocentriccaseseriesandsystematicreviewoftheliterature AT chisariclaragrazia autologoushematopoieticstemcelltransplantationinmultiplesclerosispatientsmonocentriccaseseriesandsystematicreviewoftheliterature AT toscanosimona autologoushematopoieticstemcelltransplantationinmultiplesclerosispatientsmonocentriccaseseriesandsystematicreviewoftheliterature AT arenasebastiano autologoushematopoieticstemcelltransplantationinmultiplesclerosispatientsmonocentriccaseseriesandsystematicreviewoftheliterature AT finocchiarochiara autologoushematopoieticstemcelltransplantationinmultiplesclerosispatientsmonocentriccaseseriesandsystematicreviewoftheliterature AT ciminovincenzo autologoushematopoieticstemcelltransplantationinmultiplesclerosispatientsmonocentriccaseseriesandsystematicreviewoftheliterature AT milonegiuseppe autologoushematopoieticstemcelltransplantationinmultiplesclerosispatientsmonocentriccaseseriesandsystematicreviewoftheliterature |